Security
HKPD · Cellyan Biotechnology Co., Ltd
HKPDNASDAQCommon stockCurrentCIK 2007702Updated Sep 24, 2026
HKPD price & chart
Loading TradingView…
NASDAQ:HKPD on TradingView ↗About the company
Cellyan Biotechnology is a Cayman Islands exempted company, and each of the HK Subsidiaries is a Hong Kong company. Currently, there are no restrictions or limitations under the laws of Hong Kong on (i) foreign exchange or the conversion of HK dollars into foreign currencies and the remittance of currencies out of Hong Kong, (ii) the transfer of cash or other assets between Cellyan Biotechnology and any of the HK Subsidiaries, across borders, or to U.S. investors, or (iii) the distribution of earnings from the HK Subsidiaries to Cellyan Biotechnology or U.S. investors. However, if certain PRC laws and regulations, including existing laws and regulations and those enacted or promulgated in the future, were to become applicable to our HK Subsidiaries, to the extent our cash or assets are in Hong Kong or with a Hong Kong entity, such funds or assets may not be available to fund operations or for other use outside of Hong Kong due to interventions in or the imposition of restrictions and limitations on the HK Subsidiaries’ ability to transfer funds or assets by the PRC government. We cannot assure you that the PRC government will not intervene or impose restrictions on the HK Subsidiar…
In the news
Hong Kong Pharma Digital Technology Holdings Limited Reports Financial Results for the Six Months Ended September 30, 2024 News provided by Hong Kong Pharma Digital Technology Holdings Limited Mar 28, 2025, 04:50 ET Share this article Share to X Share this article Share to X HONG KONG , March 28, 20 ↗
Hong Kong Pharma Digital Technology Holdings Limited Announces Closing of Initial Public Offering News provided by Hong Kong Pharma Digital Technology Holdings Limited Jan 16, 2025, 14:10 ET Share this article Share to X Share this article Share to X NEW YORK , Jan. 16, 2025 /PRNewswire/ -- Hong Kon ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
cash flow · annual statements
| Line item | FY 2025 |
|---|---|
| Cash flows from operating activities: | |
| Profit or LossUSD | -27,056Source |
| Additional Financial Items | |
| AdjustmentsForFinanceCostsUSD | 43,145Source |
| IncomeTaxesPaidRefundClassifiedAsOperatingActivitiesUSD | 294,831Source |
| InterestPaidClassifiedAsOperatingActivitiesUSD | 97,667Source |
| PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivitiesUSD | 1,002,588Source |
| ProceedsFromBorrowingsClassifiedAsFinancingActivitiesUSD | 769,922Source |
| ProceedsFromIssuingSharesUSD | 4,000,000Source |
| PurchaseOfIntangibleAssetsClassifiedAsInvestingActivitiesUSD | 85,072Source |
| RepaymentsOfBorrowingsClassifiedAsFinancingActivitiesUSD | 237,826Source |
income statement · annual statements
| Line item | FY 2025 |
|---|---|
| Cost of Goods and Services Sold | — |
| Selling, General and Administrative ExpenseUSD | 2,215,859Source |
| Total RevenueUSD | 20,313,818Source |
| Additional Financial Items | |
| ApplicableTaxRatenumber | 0.17Source |
| AverageEffectiveTaxRatenumber | 1.75Source |
| BasicEarningsLossPerShareUSD per share | -0Source |
| CurrentTaxExpenseIncomeUSD | 63,168Source |
| DepreciationAndAmortisationExpenseUSD | 66,091Source |
| DilutedEarningsLossPerShareUSD per share | -0Source |
| FinanceCostsUSD | 97,667Source |
| FinanceIncomeUSD | 1,741Source |
| GrossProfitUSD | 2,415,159Source |
| IncomeTaxExpenseContinuingOperationsUSD | 63,168Source |
| InterestExpenseOnLeaseLiabilitiesUSD | 34,775Source |
| OtherIncomeUSD | 1,466Source |
| ProfitLossAttributableToOwnersOfParentUSD | -27,056Source |
| ProfitLossBeforeTaxUSD | 36,112Source |
| ProfitLossFromOperatingActivitiesUSD | -2,284,587Source |
| TaxRateEffectOfForeignTaxRatesnumber | 1.87Source |